cilnidipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, nifedipine derivatives 642 132203-70-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • FRC-8653
  • cilnidipine
  • cinaldipine
  • cinalong
has excitatory & inhibitory action on the Ca+ channels in the rabbit basilar artery; structure given in first source; RN given is for (+-) isomer
  • Molecular weight: 492.53
  • Formula: C27H28N2O7
  • CLOGP: 5.54
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 1
  • TPSA: 117
  • ALOGS: -5.94
  • ROTB: 12

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Renal impairment 56.48 30.34 27 846 75634 50528617
Hepatic function abnormal 48.59 30.34 19 854 32662 50571589

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral infarction 56.42 28.65 27 1531 24648 29548321
Hyperkinetic heart syndrome 49.31 28.65 8 1550 110 29572859
Hepatic function abnormal 42.07 28.65 26 1532 39233 29533736
Interstitial lung disease 41.95 28.65 30 1528 57688 29515281
Renal impairment 41.00 28.65 34 1524 81299 29491670
Stress cardiomyopathy 37.73 28.65 10 1548 1614 29571355
Cardiac vein perforation 35.31 28.65 5 1553 25 29572944
Echocardiogram abnormal 33.36 28.65 8 1550 863 29572106

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic function abnormal 83.53 28.30 45 2734 64268 64431685
Renal impairment 79.38 28.30 57 2722 134960 64360993
Cerebral infarction 71.45 28.30 35 2744 41009 64454944
Hyperkinetic heart syndrome 50.26 28.30 8 2771 120 64495833
Interstitial lung disease 41.39 28.30 34 2745 97698 64398255
Hyperkalaemia 38.32 28.30 33 2746 101096 64394857
Cardiac vein perforation 36.31 28.30 5 2774 25 64495928
Hyperuricaemia 34.94 28.30 14 2765 10177 64485776
Platelet count decreased 34.16 28.30 39 2740 167672 64328281
Embolic stroke 33.02 28.30 12 2767 6699 64489254
Stress cardiomyopathy 29.27 28.30 12 2767 9245 64486708
Echocardiogram abnormal 29.23 28.30 8 2771 1781 64494172
Nephrogenic anaemia 28.42 28.30 9 2770 3316 64492637

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C08CA14 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Dihydropyridine derivatives
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
CHEBI has role CHEBI:35554 cardiovascular agent
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:38215 calcium channel blockers

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.67 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-gated L-type calcium channel Ion channel BLOCKER SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel IC50 4.62 CHEMBL
Voltage-dependent N-type calcium channel subunit alpha-1B Ion channel IC50 4.58 CHEMBL
Voltage-dependent N-type calcium channel subunit alpha-1B Ion channel BLOCKER IC50 6.70 IUPHAR

External reference:

IDSource
D01173 KEGG_DRUG
C0378675 UMLSCUI
CHEBI:31399 CHEBI
CHEMBL452076 ChEMBL_ID
DB09232 DRUGBANK_ID
C065927 MESH_SUPPLEMENTAL_RECORD_UI
7767 IUPHAR_LIGAND_ID
6880 INN_ID
97T5AZ1JIP UNII
5282138 PUBCHEM_CID
010899 NDDF
1177123004 SNOMEDCT_US
1179035008 SNOMEDCT_US

Pharmaceutical products:

None